Sero Survey Shows COVID-19 Antibodies In 71% Children In Chandigarh

PGIMER is the second-best medical institute in India after AIIMS

Mumbai: A serosurvey conducted by the Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh shows that children can develop antibodies against Covid-19.

The PGIMER Director Dr.Jagat Ram said that according to the survey conducted by the institute among 2,700 children, 71% of samples have developed antibodies. Also Read: India Records Less Than 30,000 New COVID Cases For 3rd Day In A Row; 339 Deaths

Speaking to the ANI, he said, “We’re at the beginning of 3rd wave of Covid Pandemic. A serosurvey conducted by the PGIMER, Chandigarh among 2700 children shows 71% pf them have developed antibodies. It shows children won’t be affected disproportionately during the third wave.” The Samples were collected from Chandigarh, rural, urban areas, and slum dweller.  Also Read: India’s Cumulative COVID-19 Vaccination Coverage Exceeds 75 Cr, Over 78 Lakh Doses Administered In Last 24 Hours

The director added, “About 69 per cent to 73 per cent of children have developed antibodies. On average 71 per cent of samples have developed antibodies. We know that there are no vaccines available for children so the antibodies have developed due to COVID-19 infection. So I don’t think, the third wave will affect children.”

He added that the survey from Maharashtra and Delhi shows that about 50-75 per cent of children have developed antibodies. “So the various surveys show that third wave will not hit the children,” said Dr Jagat Ram.

Stating the peak may be delayed, he said that people must follow Covid-appropriate behavior and must take vaccination for eligible population. Breakthrough infection has been found within 6 to 10% of patients. The severity of these infections is very less.

India has by far registered around 75 crores of vaccination doses. It reported 25,404 cases ass of 13th September. The cases are below 30,000 for the 3rd day in a row.

(With ANI Inputs)

Follow us on TwitterInstagram, and like us on Facebook for the latest updates and interesting stories. 

Show More

Adblock Detected

Please consider supporting us by disabling your ad blocker